Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 5:15 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 390 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: ZILRETTA Clear all

Conditions: Humeral Fractures
Interventions: kenalog, Lidocaine; Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 90 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: HTLV-I Infection, T Cell Leukemia
Interventions: daclizumab; Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 10 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2011
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Recurrent Adult Hodgkin Lymphoma
Interventions: basiliximab, carmustine, etoposide, cytarabine, melphalan, pharmacological study, laboratory biomarker analysis, autologous hematopoietic stem cell transplantation, yttrium Y 90-labeled basiliximab; Biological · Drug · Other + 1 more
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2024
U.S. locations: 1
States / cities: Duarte, California

Conditions: Full-thickness Rotator Cuff Tear, Rotator Cuff Tendinitis
Interventions: Ketorolac, Marcaine, Kenalog; Drug
Lead sponsor: Michael Khazzam; Other
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Keloid, Keloid of Ear Lobe, Healthy Adults
Interventions: Biopsy and/or triamcinolone injection, Excisional Biopsy; Procedure
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2023
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Liver Cancer
Interventions: TAC-101; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years to 80 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2005
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Osteoarthritis of the Shoulder, Osteoarthritis of the Hip
Interventions: FX006 32 mg, TAcs 40 mg; Drug
Lead sponsor: Pacira Pharmaceuticals, Inc; Industry
Eligibility: 40 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 6
States / cities: El Cajon, California • La Mesa, California • San Diego, California + 3 more

Conditions: Osteoarthritis, Knee
Interventions: Cingal, Triamcinolone Hexacetonide (TH), Placebo; Drug
Lead sponsor: Anika Therapeutics, Inc.; Industry
Eligibility: 40 Years to 75 Years
Enrollment: 231 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 26
States / cities: Chandler, Arizona • Tucson, Arizona • Anaheim, California + 21 more

Conditions: Breast Cancer
Interventions: Docetaxel,doxorubicin, cyclophosphamide; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 70 Years · Female only
Enrollment: 3,299 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2013
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Uveitis
Interventions: Daclizumab (Zenapax); Drug
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2007
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Nasal Obstruction, Chronic Rhinitis
Interventions: Oxymetazoline + Triamcinolone; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Knee Osteoarthritis, Total Knee Replacement
Interventions: Telephonic Active Coaching (Motivational Interviewing) + Financial Incentives, Wrist based activity tracker wear, Basic Study Activities; Behavioral · Other
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 40 Years to 85 Years
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 5
States / cities: Chicago, Illinois • Kansas City, Kansas • Boston, Massachusetts + 2 more

Conditions: Atopic Dermatitis
Interventions: Lebrikizumab, Topical Corticosteroid Creams (Triamcinolone acetonide 0.1% and Hydrocortisone 2.5%); Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 12
States / cities: Encino, California • Granada Hills, California • Mission Viejo, California + 9 more

Conditions: Leukemia, Lymphoma
Interventions: LMB-2 immunotoxin; Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1996
U.S. locations: 2
States / cities: Bethesda, Maryland

Conditions: Nasal Polyps
Interventions: Triamcinolone, Saline soaked sponge; Drug
Lead sponsor: Steward St. Elizabeth's Medical Center of Boston, Inc.; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Brighton, Massachusetts

Conditions: Arthritis
Interventions: Micro-Fragmented Adipose Tissue (MFAT), Triamcinolone Acetonide 10mg/mL; Biological · Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: New York, New York

Conditions: Graft Versus Host Disease, GVHD
Interventions: Panobinostat, Sirolimus, Tacrolimus; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Hematologic Malignancy
Interventions: Abatacept; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Trigger Finger Disorder
Interventions: Triamcinolone, Dexamethasone; Drug
Lead sponsor: Ericka Lawler; Other
Eligibility: 18 Years to 100 Years
Enrollment: 69 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Low Education, Cognition, Cognitive Training, Polyphenols
Interventions: Speed of processing training, MIND foods, Cognitive training control, Control foods; Behavioral
Lead sponsor: Indiana University; Other
Eligibility: 60 Years and older
Enrollment: 212 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Breast Cancer
Interventions: cyclophosphamide, docetaxel, doxorubicin hydrochloride, Trastuzumab, Carboplatin, Paclitaxel; Drug · Biological
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years to 120 Years
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2027
U.S. locations: 1
States / cities: Duarte, California

Conditions: Bilateral Knee Osteoarthritis
Interventions: FX006 32 mg, TAcs 40 mg; Drug
Lead sponsor: Pacira Pharmaceuticals, Inc; Industry
Eligibility: 40 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 3
States / cities: Torrance, California • Rochester, New York • Duncansville, Pennsylvania

Conditions: Hip Osteoarthritis
Interventions: Platelet Rich Plasma Joint Injection, Corticosteroid Injection; Device · Drug
Lead sponsor: LifeBridge Health; Other
Eligibility: 21 Years to 80 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Macular Edema, Cystoid, Retinal Vein Occlusion
Interventions: Standard Care, intravitreal triamcinolone injection; Other · Drug
Lead sponsor: The Emmes Company, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 682 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Madison, Wisconsin

Search by objective public record fields.

Glenohumeral Cortisone Injection

Anti-Tac for Treatment of Leukemia

Radiolabeled Monoclonal Antibody Therapy and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Primary Refractory or Relapsed Hodgkin Lymphoma

Effectiveness of Corticosteroid vs Ketorolac Shoulder Injections

Gene Expression and Biomarker Profiling of Keloid Skin

TAC-101 in Treating Patients With Advanced Hepatocellular Carcinoma (Liver Cancer)

Study to Compare Exposure of TA Following Administration of FX006 or TAcs in Patients With OA of the Shoulder or Hip

Study of Cingal® and Triamcinolone Hexacetonide for the Relief of Knee Osteoarthritis Pain

Docetaxel in Breast Cancer

ANTI-TAC THERAPY FOR UVEITIS

Steroid Treatment for Elimination of Rebound Obstruction From Intranasal Decongestants

Knee Arthroplasty Activity Trial

A Study to Evaluate the Safety of Lebrikizumab Compared to Topical Corticosteroids in Adult Patients With Atopic Dermatitis

Immunotoxin in Treating Patients With Leukemia or Lymphoma

Treatment of Early Nasal Polyposis With Topical Triamcinolone

Autologous Intra-Articular Micro-Fragmented Adipose Transfer for the Treatment of Thumb Carpometacarpal Joint Arthritis

Panobinostat (LBH589): Acute Graft Versus Host Disease (aGVHD) Prevention

HMCT/CT2401: Abatacept GVHD Prophylaxis Following Omidubicel HCT

Long Term Effectiveness of Trigger Finger Injections With Triamcinolone vs. Dexamethasone

MINDSpeed Food and Brain Training RCT

Combination Chemotherapy With or Without Trastuzumab in Treating Patients With Stage II or Stage III Breast Cancer

Study to Compare Exposure of TA Following Administration of Either FX006 or TAcs in Patients With Bilateral Knee OA

Platelet Rich Plasma Versus Corticosteroids in Hip Osteoarthritis Pain

The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study